Brief: Aravive Announces First Patient Dosed In Phase 1B/2 Clinical Trial Of AVB-500
09/08/2021 12:12
Aug 9 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2
CLINICAL
TRIAL OF AVB-500 FOR THE TREATMENT OF PANCREATIC ADENOCARCINOMA
Source text for Eikon: ID:nGNX5B8VLF
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))